Latest News
Depressive Symptoms Linked With Risk for Opioid Misuse in Adults with PTSD
Mind-Body Therapy May Be Effective for Opioid-Treated Pain
Treatment-Resistant Depression Linked to Cohabitation, Migraine, and More
Nitrogen Dioxide May Raise Schizophrenia Risk, Even When Accounting for Polygenic Factors
Paliperidone May Reduce Risk for Severe Hepatic Outcomes in Patients With Schizophrenia and Hepatitis
Shared Genetic Liability Observed for Schizophrenia, Psychosis in Alzheimer Disease
Syndemic Effects May Explain Ethnic Disparities in Psychotic Experiences
In Adolescents, Psychotic-Like Experiences Predict Future Psychiatric Illness
Pimavanserin Effective Against MDD in Antidepressant Nonresponders
More Hospital Days Seen With Antipsychotic Use in Alzheimer Disease
Cannabis Use Disorder Up With Recreational Pot Legalization
Moods During Depressive Episodes Differ in Bipolar and Major Depressive Disorders
Maternal Bacterial Infection in Pregnancy Raises Offspring Psychosis Risk
Obesity in Childhood Linked to Reduced Cortical Thickness, Executive Functioning
Stellate Ganglion Block Treatment Evaluated for PTSD
Depression in Cancer May Be Prevented With Safe Interventions
Managing Refractory Psychosis in the Real World
Scarce Evidence for Efficacy of Cannabinoid Treatment for Mental Disorders
Transcranial Direct Current Stimulation May Provoke Anxiety Response
Latest Features
Implications of Menopause in Schizophrenia Treatment
Investigators posit that endogenous estrogen may have a protective effect against schizophrenia.
How I Treat Adult Schizophrenia With Paliperidone
Asim Shah, MD, and Syed Z. Iqbal, MD, discuss the use of paliperidone to treat adult patients with schizophrenia.
Is Placebo Use Questionable in Schizophrenia Relapse Studies?
Researchers weigh in on the use of placebo-controlled trials in schizophrenia.
Changes in Appetite and Inflammation in Major Depressive Disorder
Investigators found data that showed a ghrelinergic signaling mechanism may be responsible for increased appetite in patients with MDD.
A New Center at Johns Hopkins Builds the Case for Psychedelic Research
A newly established center at Johns Hopkins is reinvigorating research on the potential therapeutic applications of psychedelics.
